# Beijing Mygenostics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-mygenostics-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.mygeno.cn
- Total disclosed funding: $16M
- Latest round: Series C (Jan 16, 2022)
- Investors on record: 3

## About

Established in 2011 and based in Beijing, China, Beijing Mygenostics Co., Ltd. is a gene technology company that focuses on the research and development of gene capture reagent products. In 2020, the company had gotten the qualification of COVID-19 testing by Beijing Health Care Commission. In January 2022, Beijing Mygenostics Co., Ltd. raised CNY 100 million in series C from Fosun Health Capital.

The company has obtained 34 patented technologies, undertaken three science and technology projects of Beijing Science and Technology Commission, and co-authored more than 310 academic SCI papers. The company also has the patent for the design and manufacture of DNA capture probes. The company's products can be categorized into five different categories which are genetic testing, tumor detection, pathogen detection, health screening and COVID-19 testing. Products within include Nucleic Acid Extraction Kit, SARS-CoV-2 Real-time RT-PCR Diagnostic Panel, Automated liquid handler SIRO-3000, Biotin-16-UTP and etc.

The company will focus on research and development of laboratory developed test(LDT) products, construction of gene big database and registration of clinical in vitro diagnostic(IVD) products and the construction of a marketing network system.

## Funding rounds

- Series C, Jan 16, 2022, $16M — Guangzhou Tianhui Capital Management, Fosun Health Capital
- Series B, Jul 27, 2015 — Prophet Capital

## Investors

- Prophet Capital (https://capitalatlas.ai/funds/prophet-capital) — Series B
- Guangzhou Tianhui Capital Management — Series C
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series C